港股異動 | 繼昨日暴跌73.4%後 凌鋭控股繼續下挫逾12%
格隆匯4月24日丨凌鋭控股(00784.HK)昨日午後突急瀉逾70%,低見0.375港元,最終收報0.405港元,跌1.115港元或73.4%,成交2.2億港元。凌鋭控股今日盤初繼續下挫逾12%,報0.355港元,總市值僅剩2.84億港元。凌鋭去年被證監會點名股權高度集中,2名主要股東合共持有約6億股,相當於已發行股本逾70%。凌鋭昨日盤後公告稱,得悉今日股價及成交量波動,作出合理查詢後,並不知悉相關原因。值得注意的是,凌鋭股價於1月20日已暴跌一次,當時單日跌逾五成。凌鋭公佈主席李劍明於1月17日以每股平均價2.6港元出售1000萬股,即涉2600萬港元,有關股份佔約1.25%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.